Samsung Bioepis Nudges Closer To Ranibizumab Approvals With New Data

Similarity Data To Be Presented At 2021 ARVO Meeting

Eye
The first biosimilar to Lucentis is expected to launch in the US in the second half of 2021 • Source: Shutterstock

More from Biosimilars

More from Products